GPCR dimerization in AD: From brain expression to therapeutic potential. University of Antwerp
GPCR targets are considered highly "druggable" and a growing interest in GPCRs forming hetero- or homodimers as possible newpharmacological targets in a variety of diseases, including AD and related dementias, has been expressed. The translation ofGPCR heterodimers and mosaics to pharmaceutical drug discovery and development is however in its infancy and hampered bythe lack of appropriate tools to study these bioconjugates, as well as ...